Glatiramer in the treatment of multiple sclerosis
Authors Syed A Rizvi, Edward Kim
Published 15 September 2006 Volume 2006:1(3) Pages 283—289
Syed A Rizvi, Edward Kim
Jennifer Moodie Department of Clinical Neurosciences, Brown Medical School, Rhode Island Hospital, Providence, RI, USA
Abstract: Multiple sclerosis (MS) is a disease of the central nervous system with both an inflammatory and degenerative component. The disease primarily affects young adults and results in significant physical and cognitive disability. Several disease-modifying agents are currently used in the management of multiple sclerosis. Glatiramer acetate (GA, Copaxone®, co-polymer 1) is a disease-modifying agent approved for the treatment of relapsing remitting multiple sclerosis. Apart from its unique mode of action, there is evidence pointing toward a possible neuroprotective role. This review will critically discuss GA’s potential mechanisms of action, the results of clinical trials, safety profile, and future directions of treatment.
Keywords: multiple sclerosis, disease-modifying agents, glatiramer acetate, clinical trials, MRI, neurodegeneration